Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Dear Ms Pegs1, if I understood correctly, you will be asking your pulmonologist for Zyesami IV off-label once approved to market 2021, yes? Once Zyesami IV is approved to market, what is to keep Zyesami inhaler from going to market as well …2021? Get that one off-label as well!!! >>>>

The most abundant neuropeptide in the lung is the vasoactive intestinal peptide (VIP), which is a potent muscle relaxant and has therefore been suggested in the therapy of chronic inflammatory lung diseases, including COPD [15,16]. In experimental conditions, VIP has a positive inotropic and chronotropic effect.

https://www.karger.com/Article/Fulltext/439228

ALSO KNOWN AS VIP, THE FINAL MAGIC WAND